| Literature DB >> 33459393 |
Ehsan Safai Zadeh1, Björn Beutel2, Christoph Frank Dietrich3, Corinna Ulrike Keber4, Katharina Paulina Huber1, Christian Görg1, Corinna Trenker5.
Abstract
PURPOSE: To describe perfusion patterns of peripheral pulmonary lesions (PPLs) in COVID-19 patients using contrast-enhanced ultrasound (CEUS). PATIENTS AND METHODS: From April 2020 until July 2020, 11 consecutive patients with RT-PCR-confirmed COVID-19 and PPLs sized over 5 mm were investigated by B-mode ultrasound (B-US) and CEUS. The homogeneity of enhancement (homogeneous and inhomogeneous) was examined retrospectively using CEUS. An inhomogeneous enhancement was defined as a perfused lesion with coexisting non-perfused areas (NPA).Entities:
Keywords: CEUS; COVID-19; SARS-CoV-2; histopathological correlation; peripheral pulmonary perfusion disturbance; ultrasound
Mesh:
Substances:
Year: 2021 PMID: 33459393 PMCID: PMC8014529 DOI: 10.1002/jum.15624
Source DB: PubMed Journal: J Ultrasound Med ISSN: 0278-4297 Impact factor: 2.754
Demographic and Clinical Data for the 11 Patients in the Study
| Patient Number | Sex | Age | Comorbidity | ICU Admission | Histological Examination of the Lung Tissue |
|---|---|---|---|---|---|
| 1 | m | 79 | No known comorbidity in the medical history |
|
|
| 2 | m | 23 | Spastic tetraplegia and cerebral shunts due to myelomeningocele |
|
|
| 3 | m | 52 | Glioblastoma WHO IV |
| |
| 4 | m | 39 | Arterial hypertension and active hepatitis B |
|
|
| 5 | m | 73 | Arterial hypertension, chronic kidney disease, and chronic lymphocytic leukemia |
|
|
| 6 | f | 62 | Rheumatoid arthritis |
|
|
| 7 | m | 70 | Arterial hypertension, diabetes mellitus, chronic kidney disease in post‐kidney transplant status, hyperlipidemia, and first‐degree atrioventricular block |
|
|
| 8 | m | 54 | Arterial hypertension, diabetes mellitus, and heart failure |
|
|
| 9 | m | 85 | Arterial hypertension, atrial fibrillation, and cerebral infarction |
|
|
| 10 | m | 65 | No known comorbidity in the medical history |
|
|
| 11 | m | 54 | Arterial hypertension, hyperlipidemia, and adiposity |
|
|
Abbreviations: f, female; ICU, intensive care unit; m, male.
Figure 1Histologic changes in the lung of patient #4 show vasculitis, microthrombi, and subsequent obliteration of small vessels. (A) and (B) Perivascular lymphocytic infiltrate (*), indicating vasculitis, with interposed several‐day‐old bleeding residues (arrows), implying previous vascular damage. Panel (B) is a higher magnification of panel (A). Arrowheads demark endothelial lining, also infiltrated by leucocytes. (C) Microthrombus in alveolar capillary (square). (D) Smaller obliterated vessels (rhombus), presumably after vasculitis or thrombosis. Scale bar: 100 μm, respectively
Laboratory Data for the 11 Patients in the Study
| Laboratory Values | D‐dimer (mg/L FEU) | C‐reactive Protein (mg/L) | Ferritin (μg/L) | Interleukin‐2 receptor (kU/L) | Interleukin‐6 (pg/ml) | TNF‐α (ng/L) |
|---|---|---|---|---|---|---|
| Normal range | 0–0.5 | <5 | 30–400 | 230–920 | <7 | <8.1 |
| Pt. 1 | 33.10 ↑ | 246.8 ↑ | 14691↑ | 3234 ↑ | 496 ↑ | 13.9 ↑ |
| Pt. 2 | 2.76 ↑ | 221.1 ↑ | 415 ↑ | 616 | 104 ↑ | <4 |
| Pt. 3 | 3.72 ↑ | 41.5 ↑ | 118 | 793 | 28 ↑ | 11.6 ↑ |
| Pt. 4 | 2.34 ↑ | 60.6 ↑ | 233 | 1003 ↑ | 26 ↑ | 11.1 ↑ |
| Pt. 5 | 0.98 ↑ | 53.2 ↑ | 3371 ↑ | 1967 ↑ | 157 ↑ | <5 |
| Pt. 6 | 0.72 ↑ | 35.5 ↑ | 673 ↑ | 1402 ↑ | 8 ↑ | 10.6 ↑ |
| Pt. 7 | 17.63 ↑ | 5.0 ↑ | 285 | 417 | 6 | 12.0 ↑ |
| Pt. 8 | 0.86 ↑ | 7.8 ↑ | 611 ↑ | 2711 ↑ | 8 ↑ | 27.8 ↑ |
| Pt. 9 | 0.82 ↑ | 55 ↑ | 230 | 642 | 36 ↑ | 5.8 |
| Pt. 10 | 1.21 ↑ | 93.0 ↑ | 642 ↑ | 1892 ↑ | 41 ↑ | 13.3 ↑ |
| Pt. 11 | 0.87 ↑ | 63.9 ↑ | 1334 ↑ | 889 | 31 ↑ | 11.4 ↑ |
Abbreviations: FEU, fibrinogen equivalent units; kU/L, kilo unit per liter; mg/L, milligram per liter; μg/l, microgram per liter; ng/L, nanogram per liter; pg/ml, picogram per milliliter; Pt, patient.
B‐US Data for the 11 Patients in the Study
| Patient Number | Ri/Le PE | Ri/Le B‐line | Ri/Le Frag | Ri/Le PPLs (size) | Ri/Le Airb |
|---|---|---|---|---|---|
| 1 | −/− | +/+ | +/+ | +/+ (0.5 cm) | −/− |
| 2 | −/+ | +/+ | −/− | −/+ (3 cm) | −/+ |
| 3 | −/− | +/+ | +/− | +/− (0.5 cm) | −/− |
| 4 | −/− | +/+ | +/+ | +/+ (0.5 cm) | −/− |
| 5 | −/− | +/+ | +/− | +/− (2 cm) | −/− |
| 6 | −/− | +/+ | −/+ | −/+ (3 cm) | −/+ |
| 7 | −/+ | +/+ | +/+ | +/+ (6 cm) | −/+ |
| 8 | +/+ | +/+ | −/− | −/+ (4 cm) | −/− |
| 9 | −/+ | +/+ | −/− | −/+ (6 cm) | −/− |
| 10 | −/+ | +/+ | −/− | +/+ (4 cm) | −/− |
| 11 | −/− | +/+ | −/+ | +/− (2 cm) | −/− |
Abbreviations: Airb, air bronchogram; Frag, fragmented pleura; Le, left side; PE, pleural effusion; PPLs, peripheral pulmonary lesions; Ri, right side.
Figure 2A 24‐year‐old male patient with RT‐PCR‐confirmed COVID‐19. (A) B‐US shows a small amount of effusion, with inhomogeneous lung consolidation. (B) CEUS after 5 seconds shows a pulmonary arterial enhancement, with small peripheral non‐perfused areas (NPA) (*). (C) Higher magnification of the area marked by a red rectangle in panel (B). Arrowheads demark the non‐perfused area during the complete CEUS examination. (D) Graphical illustration of panel (C).
Figure 3A 54‐year‐old male patient with RT‐PCR‐confirmed COVID‐19. (A) B‐US shows a small amount of effusion, with homogeneous peripheral lung consolidation. (B) CEUS after 21 seconds shows a bronchial arterial enhancement at the edge, with complete non‐enhancement of the lesion (*). (C) Higher magnification of the area is marked by a red rectangle in panel (B). Arrowheads demark the non‐perfused area during the complete CEUS examination. (D) Graphical illustration of panel (C).
CEUS Data for the 11 Patients in the Study
| Patient Number | HE (peripheral inhomogeneous) | Size of NPA | Number of Lesions |
|---|---|---|---|
| 1 | + | <1 cm | Multiple |
| 2 | + | <1 cm | Multiple |
| 3 | + | <1 cm | Solitary |
| 4 | + | <1 cm | Solitary |
| 5 | + | >1 cm | Multiple |
| 6 | + | <1 cm | Multiple |
| 7 | + | <1 cm | Multiple |
| 8 | + | >1 cm | Multiple |
| 9 | + | <1 cm | Solitary |
| 10 | + | >1 cm | multiple |
| 11 | + | <1 cm | multiple |
Abbreviations: HE, homogeneity of enhancement; NPA, non‐perfused area.